Arch Dis Child 2000;83:313-316 ( October )

Article

Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort Simon J Clark^a, Michael W Beresford^b, N V Subhedar^b, N J Shaw^b

^a University of Liverpool, Liverpool, UK, ^b Neonatal Unit, Liverpool Women's Hospital, Liverpool, UK

Correspondence to: Dr S Clark, Neonatal Unit, Liverpool Women's Hospital, Crown Street, Liverpool L8 7SS, UK email: rvecho{at}yahoo.com

Accepted 16 May 2000

BACKGROUNDBronchiolitis caused by respiratory syncytial virus (RSV) is an important cause of morbidity in ex-premature infants. In a randomised placebo controlled trial monoclonal antibody prophylaxis showed a 55% reduction in relative risk of hospital admission for these high risk infants, against a background incidence of 10.6 admissions per 100 high risk infants.
AIMSTo follow a cohort of high risk infants in order to assess hospitalisation rate from RSV and the potential impact of prophylaxis for these patients in a UK local health authority.
METHODSA cohort of high risk infants from a local health authority were followed over the 1998/99 and 1999/2000 RSV seasons. The high risk population was defined as infants who, at the beginning of the seasons studied, were: (1) under 6 months old and born prior to 36 weeks gestation with no domiciliary oxygen requirement; or (2) under 24 months of age and discharged home in supplemental oxygen. All admissions with bronchiolitis during the season were identified.
RESULTSA total of 370 high risk infants were identified for the 1998/99 season and 286 for the following year. Over the two years there were 68 admissions. Significantly more admissions occurred from group 2 infants. RSV was identified in 27 cases (four admissions per hundred high risk infants). Prophylaxis may have saved up to £195 134 in hospital costs over the two years, but would have cost £1.1 million in drug acquisition costs.
CONCLUSIONSCareful consideration of risk factors is needed when selecting infants for RSV prophylaxis.


Keywords: respiratory syncytial virus; bronchiolitis; epidemiology; neonatal infections; prematurity; chronic lung disease

---

© 2000 by Archives of Disease in Childhood
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Use of acetazolamide to decrease cerebrospinal fluid production in chronically ventilated patients with ventriculopleural shunts

E Carrion, J H Hertzog, M D Medlock, G J Hauser, and H J Dalton
Arch. Dis. Child. 2001 84: 68-71. [Abstract] [Full Text] [PDF]

HARVEY MARCOVITCH
Arch. Dis. Child. 2000 83: 0. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Broughton, S, Bhat, R, Roberts, A, Zuckerman, M, Rafferty, G, Greenough, A (2006). Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants. Arch. Dis. Child. 91: 26-30 [Abstract] [Full Text]  
• Meates-Dennis, M. (2005). BRONCHIOLITIS. EDUCATION AND PRACTICE 90: ep81-ep86 [Full Text]  
• Broughton, S, Roberts, A, Fox, G, Pollina, E, Zuckerman, M, Chaudhry, S, Greenough, A (2005). Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants. Thorax 60: 1039-1044 [Abstract] [Full Text]  
• Prais, D., Danino, D., Schonfeld, T., Amir, J., for the Israeli RSV Monitoring Group, (2005). Impact of Palivizumab on Admission to the ICU for Respiratory Syncytial Virus Bronchiolitis: A National Survey. Chest 128: 2765-2771 [Abstract] [Full Text]  
• Embleton, N D, Harkensee, C, Mckean, M C (2005). Palivizumab for preterm infants. Is it worth it?. Arch. Dis. Child. Fetal Neonatal Ed. 90: F286-f289 [Abstract] [Full Text]  
• Heikkinen, T, Valkonen, H, Lehtonen, L, Vainionpaa, R, Ruuskanen, O (2005). Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch. Dis. Child. Fetal Neonatal Ed. 90: F64-F68 [Abstract] [Full Text]  
• Brown, K L, Walker, G, Grant, D J, Tanner, K, Ridout, D A, Shekerdemian, L S, Smith, J H, Davis, C, Firmin, R K, Goldman, A P (2004). Predicting outcome in ex-premature infants supported with extracorporeal membrane oxygenation for acute hypoxic respiratory failure. Arch. Dis. Child. Fetal Neonatal Ed. 89: F423-F427 [Abstract] [Full Text]  
• Deshpande, S A, Northern, V (2003). The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch. Dis. Child. 88: 1065-1069 [Abstract] [Full Text]  
• Prais, D., Schonfeld, T., Amir, J. (2003). Admission to the Intensive Care Unit for Respiratory Syncytial Virus Bronchiolitis: A National Survey Before Palivizumab Use. Pediatrics 112: 548-552 [Abstract] [Full Text]  
• van Woensel, J B M, van Aalderen, W M C, Kimpen, J L L (2003). Viral lower respiratory tract infection in infants and young children. BMJ 327: 36-40 [Full Text]  
• Greenough, A, Cox, S, Alexander, J, Lenney, W, Turnbull, F, Burgess, S, Chetcuti, P A J, Shaw, N J, Woods, A, Boorman, J, Coles, S, Turner, J, RUSSELL, G. (2001). Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch. Dis. Child. 85: 463-468 [Abstract] [Full Text]  
• BUCK, J. J, DEBENHAM, P., TASKER, R. C (2001). Prophylaxis for respiratory syncytial virus infection: missing the target. Arch. Dis. Child. 84: 373g-373 [Full Text]  
• , , , (2001). Preventing respiratory syncitial virus. BMJ 322: 62-63 [Full Text]  

eLetters:

Read all eLetters

Prophylaxis for respiratory syncytial virus infection: missing the target

Robert C Tasker

ADC Online, 2 Nov 2000 [Full text]